<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509080</url>
  </required_header>
  <id_info>
    <org_study_id>PAMIR</org_study_id>
    <nct_id>NCT00509080</nct_id>
  </id_info>
  <brief_title>Prognosis in Asymptomatic Mitral Regurgitation (PAMIR) Study</brief_title>
  <official_title>Prognosis in Asymptomatic Mitral Regurgitation (PAMIR) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schweizerische Herzstiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of BNP/NT-proBNP levels in the detection&#xD;
      of early left ventricular dysfunction and damage may improve the timing of cardiac surgery&#xD;
      and therefore the long-term management of asymptomatic patients with severe mitral&#xD;
      regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: One of the most difficult issues in the care of asymptomatic patients with severe&#xD;
      valvular heart disease, particularly mitral regurgitation, is the timing of the surgical&#xD;
      intervention. Unlike the stenotic lesions, regurgitant lesions often progress insidiously,&#xD;
      causing left ventricular damage before symptoms develop. Current criteria for surgical&#xD;
      intervention include left ventricular dimensions and left ventricular ejection fraction. The&#xD;
      clinical problem is that once these morphologic criteria are fulfilled, the prognosis has&#xD;
      already worsened, even if surgery is performed promptly. In addition, the onset of symptoms&#xD;
      may be difficult to detect because of physical inactivity or under-reporting. In some&#xD;
      patients, it may be unclear whether symptoms are related to valvular heart disease or other&#xD;
      conditions.&#xD;
&#xD;
      Natriuretic peptides including B-type natriuretic peptide (BNP) and NT-proBNP may be more&#xD;
      sensitive markers of left ventricular damage than morphologic studies such as&#xD;
      echocardiography. The use of BNP or NT-proBNP levels may help timing the surgical&#xD;
      intervention before irreversible left ventricular damage has occurred. Previous experience&#xD;
      with BNP and NT-proBNP testing in patients with valvular heart disease is limited, albeit&#xD;
      promising.&#xD;
&#xD;
      Aim: To test the hypotheses that:&#xD;
&#xD;
        -  Elevated BNP/NT-proBNP levels reflect early left and right ventricular dysfunction&#xD;
           indicating imminent congestive heart failure and cardiac decompensation, and call for&#xD;
           surgical intervention.&#xD;
&#xD;
        -  The BNP/NT-proBNP level is a more sensitive marker of ventricular damage than&#xD;
           ventricular dimensions and left ventricular ejection fraction.&#xD;
&#xD;
        -  Low BNP/NT-proBNP levels indicate a low event rate with medical therapy and may&#xD;
           therefore reassure a &quot;wait and see strategy&quot;.&#xD;
&#xD;
      Patients and methods: The prospective cohort study is designed to enrol 200 patients with&#xD;
      severe mitral regurgitation and followed over a 4-year period. Natriuretic peptides including&#xD;
      BNP and NT-proBNP will be measured in addition to detailed clinical, electrocardiographic,&#xD;
      and echocardiographic assessment prospectively and repetitively in patients with severe&#xD;
      mitral regurgitation during routine consultations at 6 months intervals. Our primary analysis&#xD;
      (longitudinal study) will focus on the prognosis in asymptomatic patients. In addition, a&#xD;
      sub-study will also include symptomatic patients with severe mitral regurgitation whether or&#xD;
      not they are scheduled to undergo valvular surgery (cross sectional study) in order to obtain&#xD;
      more reliable data regarding BNP/NT-proBNP levels in patients with a formal indication for&#xD;
      valvular surgery. The treating physician will remain blinded to the BNP/NT-proBNP values. In&#xD;
      this cohort study, we will try to identify a BNP/NT-proBNP cut-off values that predict major&#xD;
      adverse cardiac events including cardiac death, congestive heart failure, myocardial&#xD;
      infarction, or persistent left ventricular systolic dysfunction at 6 months after valvular&#xD;
      surgery.&#xD;
&#xD;
      Clinical Significance: The use of BNP/NT-proBNP levels in the detection of early left&#xD;
      ventricular dysfunction and damage may improve the timing of cardiac surgery and therefore&#xD;
      the long-term management of asymptomatic patients with severe mitral regurgitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of congestive heart failure, decompensated heart failure and valve surgery</measure>
    <time_frame>360 days</time_frame>
    <description>Elevated BNP/NT-proBNP levels reflect early left and right ventricular dysfunction indicating imminent congestive heart failure and cardiac decompensation, and call for surgical intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of congestive heart failure, decompensated heart failure and valve surgery</measure>
    <time_frame>720 days</time_frame>
    <description>Elevated BNP/NT-proBNP levels reflect early left and right ventricular dysfunction indicating imminent congestive heart failure and cardiac decompensation, and call for surgical intervention.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Regurgitation</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the participating centers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe isolated mitral regurgitation due to valvular disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing written patient consent&#xD;
&#xD;
          -  Active infective endocarditis&#xD;
&#xD;
          -  Relative mitral regurgitation due to left ventricular disease&#xD;
&#xD;
          -  Other moderate to severe dysfunctional valve&#xD;
&#xD;
          -  Previous cardiac surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Sepsis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Mueller, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerkhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Praxis Dr. Gekeler</name>
      <address>
        <city>LÃ¶rrach</city>
        <zip>79540</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Praxis Dr. Cron/ Dr. Hess</name>
      <address>
        <city>Basel</city>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Praxis Prof. A. Hoffmann</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitral regurgitation</keyword>
  <keyword>BNP</keyword>
  <keyword>NT-proBNP</keyword>
  <keyword>natriuretic peptides</keyword>
  <keyword>valvular heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

